59
Participants
Start Date
May 20, 2019
Primary Completion Date
April 23, 2021
Study Completion Date
April 23, 2021
Imsidolimab
Administered by subcutaneous injection once a month
Placebo
Administered by subcutaneous injection once a month
Investigational Site, Berlin
Investigational Site, Berlin
Investigational Site, Schwerin
Investigational Site, Hamburg
Investigational Site, Hamburg
Investigational Site, Wilmington
Investigational Site, Pembroke Pines
Investigational Site, Miami
Investigational Site, Fort Lauderdale
Investigational Site, Tampa
Investigational Site, Birmingham
Investigational Site, Columbus
Investigational Site, Plainfield
Investigational Site, Indianapolis
Investigational Site, Ann Arbor
Investigational Site, Bad Bentheim
Investigational Site, Bonn
Investigational Site, St Louis
Investigational Site, St Louis
Investigational Site, Overland Park
Investigational Site, Norman
Investigational Site, Dallas
Investigational Site, Phoenix
Investigational Site, Santa Monica
Investigational Site, Encino
Investigational Site, Portland
Investigational Site, Surrey
Investigational Site, Greater Sudbury
Investigational Site, Markham
Investigational Site, Drummondville
Investigational Site, Montreal
Investigational Site, Gdansk
Investigational Site, Katowice
Investigational Site, Lodz
Investigational Site, Olsztyn
Investigational Site, Ostrowiec Świętokrzyski
Investigational Site, Rzeszów
Investigational Site, Szczecin
Investigational Site, Wroclaw
Lead Sponsor
Vanda Pharmaceuticals
INDUSTRY